IGM Biosciences Reports Major Corporate Changes
| Field | Detail |
|---|---|
| Company | Igm Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | Aug 14, 2025 |
| Risk Level | high |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.01, $1.247 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, delisting, corporate-governance, legal
TL;DR
IGM Bioscience's 8-K signals major asset changes, potential delisting, and shifts in control.
AI Summary
On August 14, 2025, IGM Biosciences, Inc. filed an 8-K report detailing several significant corporate events. These include the completion of an acquisition or disposition of assets, a notice of potential delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also covers departures or elections of directors and officers, compensatory arrangements, and amendments to articles of incorporation or bylaws.
Why It Matters
This 8-K filing indicates significant strategic shifts and potential regulatory scrutiny for IGM Biosciences, impacting its operational structure and stock listing status.
Risk Assessment
Risk Level: high — The filing mentions potential delisting and failure to meet listing standards, which poses a significant risk to the company's market presence and investor confidence.
Key Players & Entities
- IGM Biosciences, Inc. (company) — Registrant
- Palingen, Inc. (company) — Former Company Name
- August 14, 2025 (date) — Date of Report
FAQ
What specific assets were acquired or disposed of by IGM Biosciences, Inc. on or around August 14, 2025?
The filing indicates the completion of an acquisition or disposition of assets, but does not specify the details of these transactions.
What are the reasons for the notice of delisting or failure to satisfy a continued listing rule for IGM Biosciences, Inc.?
The 8-K filing states there is a notice of delisting or failure to satisfy a continued listing rule, but does not provide the specific rule or reason for this notice.
What material modifications have been made to the rights of IGM Biosciences, Inc. security holders?
The filing reports material modifications to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.
Has there been a change in control of IGM Biosciences, Inc. as reported on August 14, 2025?
Yes, the filing explicitly lists 'Changes in Control of Registrant' as an item of information being reported.
What changes have occurred regarding directors or officers at IGM Biosciences, Inc. around August 14, 2025?
The filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', indicating potential changes in leadership and compensation.
Filing Stats: 2,221 words · 9 min read · ~7 pages · Grade level 11.8 · Accepted 2025-08-14 16:03:14
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share IGMS The Nasdaq Global Se
- $1.247 — n Stock, "Shares"), in exchange for (i) $1.247 in cash per Share (the "Cash Amount");
Filing Documents
- d82965d8k.htm (8-K) — 43KB
- d82965dex31.htm (EX-3.1) — 26KB
- d82965dex32.htm (EX-3.2) — 84KB
- 0001193125-25-180763.txt ( ) — 290KB
- igms-20250814.xsd (EX-101.SCH) — 2KB
- igms-20250814_lab.xml (EX-101.LAB) — 15KB
- igms-20250814_pre.xml (EX-101.PRE) — 10KB
- d82965d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits No. Description of Exhibit 2.1+ Agreement and Plan of Merger, dated July 1, 2025, by and among Concentra Biosciences, LLC, Concentra Merger Sub V, Inc. and IGM Biosciences, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on July 1, 2025). 2.2+ Contingent Value Rights Agreement, dated August 14, 2025, by and among Concentra Biosciences, LLC, Concentra Merger Sub V, Inc., Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC (incorporated herein by reference to Exhibit (d)(5) the Schedule TO-T/A filed by Concentra Biosciences, LLC on August 14, 2025). 3.1 Amended and Restated Certificate of Incorporation of IGM Biosciences, Inc. 3.2 Amended and Restated Bylaws of the IGM Biosciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Certain schedules and annexes have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules and annexes upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any annexes or schedules so furnished.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IGM BIOSCIENCES, INC. Date: August 14, 2025 By: /s/ Mary Beth Harler, M.D. Mary Beth Harler, M.D. Chief Executive Officer